Acrivon Therapeutics shares owned by UBS Group
Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by UBS Group
from 13F filings
Historical chart of UBS Group investment in Acrivon Therapeutics
Tip: Access up to 7 years of quarterly data
All positions including Acrivon Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Acrivon Therapeutics by UBS Group
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-09-30 | $1.2M | 683k | 1.81 |
| 2025-06-30 | $540 | 455 | 1.19 |
| 2025-03-31 | $26k | 13k | 2.03 |
| 2024-12-31 | $86k | 14k | 6.02 |
| 2024-09-30 | $40k | 5.7k | 7.00 |
| 2024-06-30 | $65k | 11k | 5.80 |
| 2024-03-31 | $91k | 13k | 7.15 |
| 2023-09-30 | $974 | 102 | 9.56 |
| 2023-06-30 | $127k | 9.8k | 13.00 |
| 2023-03-31 | $68k | 5.4k | 12.68 |
| 2022-12-31 | $55k | 4.7k | 11.52 |